
-
Roivant NASDAQ:ROIV Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch "Vants" - nimble and focused biopharmaceutical and health technology companies
Location: Clarendon House, Hamilton Parish, HM 11, Bermuda | Website: roivant.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
2.907B
Cash
5.147B
Avg Qtr Burn
-193.8M
Short % of Float
12.44%
Insider Ownership
27.66%
Institutional Own.
80.12%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VTAMA (Tapinarof) Details Psoriasis | Approved Quarterly sales | |
VTAMA (Tapinarof) Details Atopic dermatitis | Approved Quarterly sales | |
Brepocitinib Details Dermatomyositis | Phase 3 Data readout | |
Batoclimab Details Eye disease , Thyroid Eye Disease | Phase 3 Data readout | |
Batoclimab Details Myasthenia gravis | Phase 3 Data readout | |
RVT-3101 Details Ulcerative colitis | Phase 3 Initiation | |
Brepocitinib Details Systemic lupus erythematosus, Chronic non-infectious uveitis, Dermatomyositis | Phase 3 Initiation | |
Mosliciguat Details Pulmonary hypertension associated with interstitial lung disease | Phase 2 Data readout | |
RVT-3101 Details Crohns disease | Phase 2 Data readout | |
Brepocitinib Details Sarcoidosis | Phase 2 Initiation | |
RVT-2001 Details Myelodysplastic syndrome | Failed Discontinued | |
Namilumab Details Sarcoidosis | Failed Discontinued |